Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000517512 | SCV000613777 | uncertain significance | not specified | 2016-11-17 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000727195 | SCV000706543 | uncertain significance | not provided | 2017-02-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000798006 | SCV000937598 | uncertain significance | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7; Autosomal recessive limb-girdle muscular dystrophy type 2U | 2022-07-26 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 93 of the ISPD protein (p.Ile93Val). This variant is present in population databases (rs762370550, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with ISPD-related conditions. ClinVar contains an entry for this variant (Variation ID: 447580). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000727195 | SCV003815679 | uncertain significance | not provided | 2019-06-27 | criteria provided, single submitter | clinical testing |